Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dazukibart - Pfizer

Next Previous
Drug Profile

Dazukibart - Pfizer

Alternative Names: PF-06823859

Latest Information Update: 12 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antibodies; Biological factors; Skin disorder therapies
  • Mechanism of Action Interferon beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dermatomyositis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dermatomyositis; Polymyositis
  • Phase II Cutaneous lupus erythematosus; Systemic lupus erythematosus
  • No development reported Lupus vulgaris

Most Recent Events

  • 20 Nov 2023 Pfizer completes the phase II trial in Dermatomyositis in USA, Germany, Hungary, Poland and Spain.(IV) (NCT05192200) (EudraCT2021-004787-10)
  • 10 Nov 2023 Efficacy data from a phase-II trial in Dermatomyositis presented at the ACR Convergence 2023 (ACR-ARP-2023)
  • 07 Jul 2023 Phase-II clinical trials in Cutaneous lupus erythematosus in Canada (IV) (NCT05879718)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top